A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

• Documented multiple myeloma (MM) as defined by the criteria: monoclonal plasma cellsin the bone marrow greater than or equal to (>=) 10 percent (%) at some point in theparticipant's disease course or presence of a biopsy-proven plasmacytoma

• Received at least 1 prior line of therapy for MM

• Documented evidence of progressive disease (PD) based on investigator'sdetermination of response as defined by the International Myeloma Working Group (IMWG) criteria on or after their last regimen

• Achieved a response (partial response [PR] or better based on investigator'sdetermination of response by the IMWG criteria) to at least 1 prior regimen

• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2

Exclusion Criteria:

• Received daratumumab or other anti-CD38 therapies

• Refractory to Velcade, or another proteasome inhibitor (PI), like ixazomib andcarfilzomib (ie, participant had progression of disease while receiving Velcadetherapy or within 60 days of ending Velcade therapy, or another PI, like ixazomiband carfilzomib, etc)

• Intolerant to Velcade (that is [ie], discontinued due to any adverse event while onVelcade treatment)

• Planning to undergo a stem cell transplant prior to progression of disease on thisstudy, that is ie, these participants should not be enrolled in order to reducedisease burden prior to transplant

• History of malignancy (other than MM) within 3 years before the date ofrandomization